

User Declaration Form for the usage of the EU- OPENSOURCE fragment library

This form regulates the use of the EU-OPENSOURCE fragment library at EU-OPENSOURCE/ EU-OPENSOURCE-DRIVE (DRIVE) and/ or iNEXT-Discovery fragment screening facilities by internal or external users. The aim of this form is to ensure that i) essential user information and ii) feedback on the screening campaign for the purpose of monitoring the performance and improving the EU-OPENSOURCE fragment library are delivered to EU-OPENSOURCE ERIC.

For multiple projects please fill in separate forms. For support and questions contact us at fragment-screening@eu-openscreen.eu

User Information

Date:

Principal Investigator (Name, Surname):

Nationality of the Principal Investigator:

Email address:

Institution (including address):

Country:

Other researcher(s) involved in the screening project (Name, Surname, email address and position):

DRIVE or iNEXT-Discovery partner or other facility that will run the screen:

Name of the contact person at the at the DRIVE/ iNEXT-Discovery/ other facility (Name, Surname and email address):

Project Information

Project title:

Project abstract (please provide a short abstract of the project including scientific background and aim of the research; max. 500 characters):



Expected start and end-date of the screening campaign:

Biological target e.g. name of the protein, RNA, or other:

Screening technology envisaged for the project:

The EU-OPENSREEN fragment library will be used for COVID-19 research activities.

User statement:

I, the PI, accept the EU-OPENSREEN ERIC conditions for reporting feedback after each screening campaign that uses the EU-OPENSREEN fragment library (details on feedback conditions are enclosed in Annex I).

I, the PI, will acknowledge EU-OPENSREEN ERIC for providing and enabling the usage of the EU-OPENSREEN fragment library in publications and/ or communication activities containing data, which was generated through the usage of the EU-OPENSREEN fragment library using the following sentence: *“The user/ external user acknowledges EU-OPENSREEN ERIC for providing its fragment library for the presented scientific work. EU-OPENSREEN ERIC has received funding from European Union’s Horizon 2020 research and innovation programme under grant agreement No 823893 (EU-OPENSREEN-DRIVE).”*

I, the PI, agree to make information on hits resulting from the use of the library publicly available in the ECBD and/ or other open-access databases such as PDBe or BMRB (for structural data not supported by the ECBD).

Please notice that an embargo period of up to 36 months can be requested during the first 6 months (this time frame of 6 months will be deducted from the total of 36 months embargo period) after the first notification of a validated hit, to allow for publication and/ or filing patent applications to secure potential intellectual property. Data will automatically be uploaded in the public domain after 6 months passed without an embargo requested.

Do you agree that EU-OPENSREEN partner sites/ EU-OPENSREEN-DRIVE partners may use the general information of your project (i.e. PI name and Institution, project title etc) for outreach and reporting purposes (respecting confidentiality of project specifics)? *In case that you do not agree, please give your explanation in the comment section below:*

Yes No

Comments (max. 500 characters):

Personal Data and Confidentiality:

EU-OPENSSCREEN commits to process personal data exchanged and received under this collaboration in line with the provisions of the General Data Protection Regulation (GDPR).

I have read and accept the EU-OPENSSCREEN ERIC privacy policy.

EU-OPENSSCREEN ERIC will regard all project-related information disclosed by the USER as confidential.

Date:

Place:

Signature:

Annex I Conditions of the feedback

After each screening of the EU-OPENSSCREEN fragment library the User needs to provide information on:

- Solubility, quality and identity problems
- Biophysical method(s) used for screening
- Biological target e.g. name of protein, RNA, other
- Number of hits, hit rate and the hit threshold
- Promiscuous binding alert (if observed)
- Full available information on hits (structure, ligand efficiency, structural information of binding)